Marina Martínez-Carmona1, Quy P Ho2,3, Jérémy Morand1, Ana García4,5, Enrique Ortega6, Luiza C S Erthal2,3, Eduardo Ruiz-Hernandez2,3, M Dolores Santana6, José Ruiz6, Maria Vallet-Regí4,5, Yurii K Gun'ko1. 1. School of Chemistry and CRANN, Trinity College, The University of Dublin (TCD), Dublin 2, Ireland. 2. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin (TCD), Dublin 2, Ireland. 3. Trinity Biomedical Sciences Institute, TCD, Dublin 2, Ireland. 4. Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, 28040 Madrid, Spain. 5. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Avenida Monforte de Lemos, 3-5, 28029 Madrid, Spain. 6. Departamento de Química Inorgánica, Universidad de Murcia, and Biomedical Research Institute of Murcia (IMIB-Arrixaca), E-30071 Murcia, Spain.
Abstract
In the process of synthesis of a new drug, as important as the drug itself is the formulation used, because the same compound can present a very different efficacy depending on how it is administered. In this work, we demonstrate how the antitumor capacity of a new octahedral organoruthenium complex, [Ru(ppy-CHO)(phen)2][PF6] is affected by its encapsulation in different types of mesoporous silica nanoparticles. The interactions between the Ru complex and the silica matrix and how these interactions are affected at two different pHs (7.4 and 5.4, mimicking physiological and endolysosomal acidic conditions, respectively) have been studied. The encapsulation has also been shown to affect the induction of apoptosis and necrosis and progression of the cell cycle compared to the free drug. The encapsulation of the Ru complex in nanoparticles functionalized with amino groups produced very high anticancer activity in cancer cells in vitro, especially against U87 glioblastoma cells, favoring cellular internalization and significantly increasing the anticancer capacity of the initial non-encapsulated Ru complex.
In the process of synthesis of a new drug, as important as the dn class="Chemical">rug itself is the formulation used, because the same compound can present a very different efficacy depending on how it is administered. In this work, we demonstrate how the antitumor capacity of a new octahedral organoruthenium complex, [Ru(ppy-CHO)(phen)2][PF6] is affected by its encapsulation in different types of mesoporous silica nanoparticles. The interactions between the Ru complex and the silica matrix and how these interactions are affected at two different pHs (7.4 and 5.4, mimicking physiological and endolysosomal acidic conditions, respectively) have been studied. The encapsulation has also been shown to affect the induction of apoptosis and necrosis and progression of the cell cycle compared to the free drug. The encapsulation of the Ru complex in nanoparticles functionalized with amino groups produced very high anticancer activity in cancer cells in vitro, especially against U87glioblastoma cells, favoring cellular internalization and significantly increasing the anticancer capacity of the initial non-encapsulated Ru complex.
Authors: Vojtech Novohradsky; Jyoti Yellol; Olga Stuchlikova; María Dolores Santana; Hana Kostrhunova; Gorakh Yellol; Jana Kasparkova; Delia Bautista; José Ruiz; Viktor Brabec Journal: Chemistry Date: 2017-10-13 Impact factor: 5.236
Authors: Minja Mladenović; Ibrahim Morgan; Nebojša Ilić; Mohamad Saoud; Marija V Pergal; Goran N Kaluđerović; Nikola Ž Knežević Journal: Pharmaceutics Date: 2021-03-28 Impact factor: 6.321